Thermo Fisher Scientific (TMO) Given New $216.00 Price Target at Morgan Stanley

Thermo Fisher Scientific (NYSE:TMO) had its target price cut by Morgan Stanley from $228.00 to $216.00 in a research note published on Wednesday morning. They currently have an overweight rating on the medical research company’s stock.

TMO has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a buy rating to a hold rating in a report on Monday, March 26th. BTIG Research began coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They issued a buy rating and a $230.00 price objective for the company. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an overweight rating in a report on Thursday, February 1st. ValuEngine raised shares of Thermo Fisher Scientific from a hold rating to a buy rating in a report on Friday, February 2nd. Finally, Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a buy rating in a report on Thursday, February 1st. Two research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific has a consensus rating of Buy and a consensus price target of $220.64.

NYSE TMO opened at $212.79 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $86,459.92, a price-to-earnings ratio of 22.70, a price-to-earnings-growth ratio of 1.59 and a beta of 1.15. Thermo Fisher Scientific has a 12-month low of $151.74 and a 12-month high of $226.44.



Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.13. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.41 EPS. research analysts forecast that Thermo Fisher Scientific will post 10.83 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Wednesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.

In related news, SVP Gregory J. Herrema sold 33,327 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the transaction, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now owns 334,622 shares of the company’s stock, valued at $70,324,159.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,827 shares of company stock valued at $19,012,672. 0.49% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in TMO. Meritage Group LP acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $201,383,000. Viking Global Investors LP acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $154,660,000. Investec Asset Management LTD increased its position in Thermo Fisher Scientific by 28.0% during the 3rd quarter. Investec Asset Management LTD now owns 2,173,381 shares of the medical research company’s stock worth $411,204,000 after purchasing an additional 475,970 shares in the last quarter. Cornerstone Investment Partners LLC increased its position in Thermo Fisher Scientific by 89.8% during the 4th quarter. Cornerstone Investment Partners LLC now owns 802,374 shares of the medical research company’s stock worth $152,355,000 after purchasing an additional 379,703 shares in the last quarter. Finally, Longview Partners Guernsey LTD increased its position in Thermo Fisher Scientific by 6.8% during the 4th quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after purchasing an additional 311,977 shares in the last quarter. Institutional investors and hedge funds own 87.67% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific (TMO) Given New $216.00 Price Target at Morgan Stanley” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/12/thermo-fisher-scientific-tmo-given-new-216-00-price-target-at-morgan-stanley.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply